This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
RPC (RES)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
RESPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Corporate Giants Likely to Gain From Q4 Earnings Next Week
by Nalak Das
Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.
UPSNegative Net Change GILDNegative Net Change TMONegative Net Change FBPositive Net Change GOOGLNegative Net Change
biotechnology medical tech-stocks transportation
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
GILDNegative Net Change VRTXNegative Net Change INCYPositive Net Change MRNANegative Net Change OPKNo Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, Atlantic Union (AUB)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AUBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
by Zacks Equity Research
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change VIRNegative Net Change
biotechnology biotechs pharmaceuticals
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
by Zacks Equity Research
Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.
LGNDPositive Net Change ICPTPositive Net Change VKTXPositive Net Change
biotechnology biotechs pharmaceuticals
The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead
by Zacks Equity Research
Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.
REGNNegative Net Change PFENegative Net Change MRKNegative Net Change LLYPositive Net Change GILDNegative Net Change
biotechnology medical pharmaceuticals
Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
PFENegative Net Change MRKNegative Net Change ALKSNegative Net Change GILDNegative Net Change
biotechnology biotechs medical
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
by Zacks Equity Research
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
PFENegative Net Change ALKSNegative Net Change VIRNegative Net Change NUVBNegative Net Change
biotechnology biotechs
New Strong Buy Stocks for January 21st
by Zacks Equity Research
ARCB, BCC, DVAX, FCX, and JBHT have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2022.
DVAXNegative Net Change FCXPositive Net Change JBHTNegative Net Change BCCPositive Net Change ARCBNegative Net Change
biotechnology transportation
5 ROE Stocks to Buy as Q4 Earnings Witness Shaky Start
by Supriyo Bose
CommScope (COMM), Microchip (MCHP), Regeneron (REGN), Bunge (BG) and Hologic (HOLX) are some of the stocks with high ROE to profit as Q4 earnings witness shaky start to the season.
REGNNegative Net Change HOLXNegative Net Change MCHPNegative Net Change BGNegative Net Change COMMPositive Net Change
agriculture biotechnology communications medical semiconductor tech-stocks
Best Growth Stocks to Buy for January 17th
by Zacks Equity Research
PFE, M, and ACN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 17, 2022
ACNNegative Net Change PFENegative Net Change MNegative Net Change
biotechnology pharmaceuticals retail
IMV Doses First Patient in the Mid-Stage Study With Keytruda
by Zacks Equity Research
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
MRKNegative Net Change ALKSNegative Net Change IMVPositive Net Change VIRNegative Net Change
biotechnology biotechs pharmaceuticals
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
BIIBNegative Net Change RHHBYNegative Net Change LLYPositive Net Change SAVANegative Net Change
biotechnology
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
BIIBNegative Net Change AMGNNegative Net Change ALLONegative Net Change MOLNPositive Net Change ABSINegative Net Change
biotechnology biotechs medical pharmaceuticals
HollyFrontier (HFC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
HFCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Titan International (TWI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
TWIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Buy Stocks for January 11th
by Zacks Equity Research
ANF, ARCO, BNTX, GSL, and KLIC have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2022.
ANFPositive Net Change KLICPositive Net Change ARCOPositive Net Change GSLNegative Net Change BNTXNegative Net Change
biotechnology semiconductor
AAR (AIR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AIRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Winnebago Industries (WGO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
WGONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
PFENegative Net Change ABBVPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings investing large-cap medical pharmaceuticals smart-health
Solid Sales Growth Makes These 5 Stocks Worth Buying Now
by Swayta Shah
Robust sales growth is vital to gauge a company's ability to sustain its business. Let's check out Nexstar Media (NXST), Universal Health (UHS), salesforce.com (CRM), Grainger (GWW) and Marvell (MRVL), as these witness top-line growth.
CRMNegative Net Change UHSNegative Net Change GWWNegative Net Change MRVLPositive Net Change NXSTNegative Net Change
biotechnology business-services consumer-discretionary industrial-products medical tech-stocks
ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IMGNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Jan 3, 2022
by Zacks Equity Research
Companies In The News Are: PFE, CTRA, AMD, XLNX, NVAX.
AMDPositive Net Change PFENegative Net Change XLNXPositive Net Change NVAXNo Net Change CTRAPositive Net Change
biotechnology oil-energy pharmaceuticals semiconductor
Here's Why Pfizer (PFE) Appears Strongly Placed for 2022
by Kinjel Shah
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver
PFENegative Net Change ARNAPositive Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology vaccines